Literature DB >> 7498233

Experience with the iodine-123 and technetium-99m labelled anti-granulocyte antibody MAb47: a comparison of labelling methods.

P Bläuenstein1, J T Locher, K Seybold, H Koprivova, G A Janoki, H R Mäcke, P Hasler, A Ammann, I Novak-Hofer, A Smith.   

Abstract

Four different methods of radiolabelling the anti-granulocyte monoclonal antibody MAb47 were compared and their influence on diagnostic value studied. The best clinical images were obtained following labelling with iodine-123 by the Iodogen method and direct labelling with technetium-99m after tris-(carboxyethyl)-phosphine treatment of MAb47 to achieve disulphide bridge reduction. 99mTc labelling using a specific ligand (MAb47-mtp), or a second method involving direct reduction with mercaptoethanol, led to an increased background activity in clinical studies, thus impeding the diagnosis of chronic disease. Fresh infections were clearly localized by all four preparations. The elimination of the activity from the blood was slower in the case of the iodinated MAb47, while the collected urine samples showed an excretion of about 10% of the injected activity per day independent of the labelling method. The results in terms of sensitivity and specificity were rather similar for all labelling methods and ranged from 90% to 99%.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7498233     DOI: 10.1007/bf01254573

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  22 in total

1.  Immunoscintigraphy of infections using 123I and 99mTc-labeled monoclonal antibodies. Advanced experiences in 230 patients.

Authors:  K Seybold; L D Frey; J Locher
Journal:  Angiology       Date:  1992-02       Impact factor: 3.619

Review 2.  White blood cell scintigraphy. Problems related to the use of monoclonal antibodies.

Authors:  J T Locher; K Seybold
Journal:  Prog Clin Biol Res       Date:  1990

3.  Assessment of the binding properties of Granuloszint.

Authors:  P A Schubiger; P H Hasler; I Novak-Hofer; P Bläuenstein
Journal:  Eur J Nucl Med       Date:  1989

4.  Reduction-mediated technetium-99m labeling of monoclonal antibodies.

Authors:  S J Mather; D Ellison
Journal:  J Nucl Med       Date:  1990-05       Impact factor: 10.057

5.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

6.  Monoclonal antibodies identify a CEA crossreacting antigen of 95 kD (NCA-95) distinct in antigenicity and tissue distribution from the previously described NCA of 55 kD.

Authors:  F Buchegger; M Schreyer; S Carrel; J P Mach
Journal:  Int J Cancer       Date:  1984-05-15       Impact factor: 7.396

7.  Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA).

Authors:  K Bosslet; G Lüben; A Schwarz; E Hundt; H P Harthus; F R Seiler; C Muhrer; G Klöppel; K Kayser; H H Sedlacek
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

8.  Immunoscintigraphic localization of inflammatory lesions: pharmacokinetics and estimated absorbed radiation dose in man.

Authors:  P H Hasler; K Seybold; R Y Andres; J T Locher; P A Schubiger
Journal:  Eur J Nucl Med       Date:  1988

9.  Immunoscintigraphic localization of inflammatory lesions: clinical experience.

Authors:  K Seybold; J T Locher; C Coosemans; R Y Andres; P A Schubiger; P Bläuenstein
Journal:  Eur J Nucl Med       Date:  1988

10.  Solving the problem of antibody interference in commercial "sandwich"-type immunoassays of carcinoembryonic antigen.

Authors:  H J Hansen; G LaFontaine; E S Newman; M K Schwartz; A Malkin; K Mojzisik; E W Martin; D M Goldenberg
Journal:  Clin Chem       Date:  1989-01       Impact factor: 8.327

View more
  2 in total

1.  Antibodies as drug carriers. II. For proteins.

Authors:  B N Rehlaender; M J Cho
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  High Yield Production and Radiochemical Isolation of Isotopically Pure Arsenic-72 and Novel Radioarsenic Labeling Strategies for the Development of Theranostic Radiopharmaceuticals.

Authors:  Paul A Ellison; Todd E Barnhart; Feng Chen; Hao Hong; Yin Zhang; Charles P Theuer; Weibo Cai; Robert J Nickles; Onofre T DeJesus
Journal:  Bioconjug Chem       Date:  2015-12-22       Impact factor: 4.774

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.